OS	overall survival
PFS	progression-free survival
ORR	overall response rate
DCR	disease control rate
HCC	hepatocellular carcinoma
BCLC	Barcelona Clinic Liver Cancer
TACE	transarterial chemoembolization
mTKI	multiple tyrosine kinase inhibitor
PD-1	programmed cell death protein-1
PD-L1	programmed cell death ligand-1
CTLA-4	cytotoxic T-lymphocyte-associated protein 4
VEGF	vascular endothelial growth factor
AFP	α-fetoprotein
ICI	immune checkpoint inhibitor
CR	complete response
HR	hazard ratio
Vp	portal vein tumour plug
MTM	macrotrabecular-massive
ESMO	European Society for Medical Oncology
EASL	European Association for the Study of the Liver
AASLD	American Association for the Study of Liver Diseases
JSH	Japanese Society of Hepatology
ABC conversion	atezolizumab plus bevacizumab followed by curative conversion